“Pimecrolimus”的意思、由来-开放百科全书

词条

Pimecrolimus

释义

Medical uses
Side effects
Pharmacology
References
External links

{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464206673
| IUPAC_name = (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)
| image = Pimecrolimus2DACS.svg
| width = 200
| image2 = Pimecrolimus ball-and-stick.png
| tradename = Elidel
| Drugs.com = {{drugs.com|monograph|pimecrolimus}}
| pregnancy_AU = B3
| pregnancy_US = C
| legal_US = Rx-only
| routes_of_administration = topical
| bioavailability = low systemic absorption
| protein_bound = 74%–87%
| metabolism = Hepatic CYP3A
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 137071-32-0
| ATC_prefix = D11
| ATC_suffix = AH02
| PubChem = 16051947
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00337
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10482089
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7KYV510875
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200686
| C=43 | H=68 | Cl=1 | N=1 | O=11
| molecular_weight = 810.453 g/mol
| smiles = Cl[C@@H]1CC[C@H](C[C@H]1OC)\\C=C(/C)[C@H]2OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@]3(O)O[C@H]([C@H](C[C@@H](C)CC(\\C)=C\\[C@@H](CC)C(=O)C[C@H](O)[C@H]2C)OC)[C@@H](OC)C[C@H]3C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31+,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KASDHRXLYQOAKZ-ZPSXYTITSA-N
}}

Pimecrolimus is an immunomodulating agent of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema). It is available as a topical cream, once marketed by Novartis (however, Galderma has been promoting the compound in Canada since early 2007) under the trade name Elidel.

Medical uses

It has been proven to be effective in various inflammatory skin diseases, e.g., seborrheic dermatitis,^[1] cutaneous lupus erythematosus,^[2] oral lichen planus,^[3] vitiligo,^[4] and psoriasis.^[5]^[6] Tacrolimus and pimecrolimus are both calcineurin inhibitors and function as immunosuppressants.^[7]

Side effects

See also: Immunosuppressants in the treatment of dermatitis

In January 2006, the United States Food and Drug Administration (FDA) announced that Elidel packaging would be required to carry a black box warning regarding the potential increased risk of lymph node or skin cancer, as for the similar drug tacrolimus. Whereas current practice by UK dermatologists is not to consider this a significant real concern and they are increasingly recommending the use of such new drugs.